TAIPEI, TAIWAN (UroToday.com) - Introduction and Objectives: To report the longterm oncological outcome associated with radical prostatectomy (RP) in a consecutive cohort of patients with high-risk prostate cancer (PC) and to identify the variables associated with disease progression.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Methods: Between 1998 and 2006, a total of 239 patients underwent RP for high-risk PC. High-risk PC was defined as follows: prostate-specific antigen (PSA) level > 20 ng/mL, Gleason score 8– 10, and/or clinical stage T2c-T4 disease. Biochemical recurrence (BCR) was defined as a postoperative PSA value ≥ 0.20 ng/mL and a confirmatory rise, or a postoperative PSA ≥ 0.20 ng/mL while receiving salvage treatment. Kaplan-Meier and multivariate cox regression analysis were used to determine BCR, cancer specific survival (CSS) and the significant predictors of BCR.
Results: The median follow-up was 64 months. Organ-confined disease, seminal vesicle invasion and lymph node metastasis were reported in 46% (64% corresponded to pT3), 27% and 3%, respectively. The positive surgical margin rate was 29%. Overall, the predicted 5-year and 10-year BCR-free survival rates were 31% and 29%, respectively; and the predicted 5-year and 10-year CSS rates were 98% and 89%, respectively. After adjusting for other covariates, higher pathologic stage, positive nodes, positive surgical margins and Gleason 8–10 are significantly associated with BCR.
Conclusions: Our data support evidence that RP can result in encouraging long-term oncologic outcomes for the management of high- risk PC.
Source of Funding: None
|Listen to an interview with Eric Barret, one of the authors of this study.|
Presented by Eric Barret,1 Youness Ahallal,1 Rafael Sanchez-Salas,1 Fernando Secin,2 Laurent Mascle,1 Petr Macek,1 Luca Lunelli,1 Camilo Gieledman,1 Marc Galiano,1 Francois Rozet,1 and Xavier Cathelineau1 at the 32nd World Congress of Endourology & SWL - September 3 - 7, 2014 - Taipei, Taiwan
1Department of Urology, Institut Montsouris- Paris-Descartes University, Paris, France
2Department of Urology, San Lazaro Foundation and CEMIC, Buenos Aires, Argentina